Literature DB >> 31934181

miR-135a acts as a tumor suppressor by targeting ASPH in endometrial cancer.

Xiaolin Chen1, Ping Jin1, Huiru Tang2, Lei Zhang1.   

Abstract

Endometrial cancer (EC) ranks as the fourth most commonly diagnosed cancer type in women worldwide. MicroRNAs (miRNAs) are important regulators with crucial roles in regulating diverse biologic processes, including tumor initiation and progression. Previous studies have demonstrated that miR-135a was correlated with tumorigenesis in various cancers. However, its expression and biologic role in EC remained to be determined. This study aimed to clarify whether miR-135a acts as a tumor suppressor in EC by regulating the expression of aspartate-β-hydroxylase (ASPH). Expression of miR-135a was measured by qRT-PCR and the results demonstrated that miR-135a was downregulated in EC cell lines compared to a normal cell line. Cell counting kit-8 (CCK-8) and wound-healing assays demonstrated that overexpression of miR-135a significantly inhibited cell proliferation and migration. Online prediction algorithm and dual luciferase activity reporter assay revealed that ASPH acts as a direct target of miR-135a. ASPH expression was downregulated in EC cell lines when miR-135a was overexpressed. Collectively, our results indicate that miR-135a targets ASPH to inhibit EC cell proliferation and migration, suggesting a tumor suppressive role of miR-135a in EC. IJCEP
Copyright © 2019.

Entities:  

Keywords:  ASPH; endometrial cancer; miR-135a; migration; proliferation

Year:  2019        PMID: 31934181

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  7 in total

1.  Identification of a MicroRNA Signature Associated With Lymph Node Metastasis in Endometrial Endometrioid Cancer.

Authors:  Kaiyou Fu; Yanrui Li; Jianyuan Song; Wangyu Cai; Wei Wu; Xiaohang Ye; Jian Xu
Journal:  Front Genet       Date:  2021-04-15       Impact factor: 4.599

2.  CircTM7SF3 contributes to oxidized low-density lipoprotein-induced apoptosis, inflammation and oxidative stress through targeting miR-206/ASPH axis in atherosclerosis cell model in vitro.

Authors:  Xiaojuan Wang; Ming Bai
Journal:  BMC Cardiovasc Disord       Date:  2021-02-02       Impact factor: 2.298

3.  miR-29a-3p inhibits endometrial cancer cell proliferation, migration and invasion by targeting VEGFA/CD C42/PAK1.

Authors:  Aizhi Geng; Lin Luo; Fengyun Ren; Ling Zhang; Haiying Zhou; Xue Gao
Journal:  BMC Cancer       Date:  2021-07-21       Impact factor: 4.430

4.  miR-135a inhibits malignant proliferation and diffusion of non-small cell lung cancer cells by down-regulating ROCK1 protein.

Authors:  Yanan Zhao; Xiaosong Sun; Kun Zhu; Min Cheng
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

Review 5.  Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).

Authors:  Wenqian Zheng; Xiaowei Wang; Jinhui Hu; Bingjun Bai; Hongbo Zhu
Journal:  Oncol Rep       Date:  2020-10-06       Impact factor: 3.906

Review 6.  Aspartate β-hydroxylase as a target for cancer therapy.

Authors:  Madiha Kanwal; Michal Smahel; Mark Olsen; Jana Smahelova; Ruth Tachezy
Journal:  J Exp Clin Cancer Res       Date:  2020-08-18

Review 7.  MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review.

Authors:  Amélia Favier; Grégoire Rocher; Annette K Larsen; Romain Delangle; Catherine Uzan; Michèle Sabbah; Mathieu Castela; Alex Duval; Céline Mehats; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2021-03-06       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.